Pre and Post-Treatment CD27+ T Cells Track with Clinical Efficacy of Axi-Cel in DLBCL Patients
Justin Chou, Jerome Ritz(Dana-Farber Cancer Institute), David B. Miklos(Stanford University), Frederick L. Locke(Moffitt Cancer Center), Mike Mattie, Caron A. Jacobson(Dana-Farber Cancer Institute), Gayatri Tiwari, Jinghui Dong(Chinese PLA General Hospital), Justin A. Budka(Gilead Sciences (United Kingdom)), Alexander T. Falk, Yohei Arihara(Sapporo Medical University), Philippe Armand(Harvard University), Scott J. Rodig(Brigham and Women's Hospital), Adrian Bot(Unknown), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Lazaros J. Lekakis(University of Miami Hospital), Armin Ghobadi(Washington University in St. Louis), Yi Lin, Lei Huang(Shanghai Normal University), Francesca Milletti
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k